Press release
Transthyretin Amyloidosis Treatment Market Exclusive Report with Detailed Study Analysis
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Transthyretin Amyloidosis Treatment Market - (By Type (ATTR-PN, ATTR-CM), By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy), By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."According to the latest research by InsightAce Analytic, the Transthyretin Amyloidosis Treatment Market is valued at US$ 5.2 billion in 2023, and it is expected to reach US$ 9.4 billion by 2031, with a CAGR of 7.90% during the forecast period of 2024-2031.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2890
Transthyretin amyloidosis (ATTR amyloidosis) treatment encompasses medical interventions designed to manage and slow the progression of this rare, progressive, and potentially fatal disease caused by the accumulation of abnormal transthyretin protein in tissues and organs. Therapeutic approaches include medications that stabilize or reduce transthyretin production, along with supportive therapies aimed at symptom management and complication prevention.
The growing awareness and improved diagnostic capabilities for identifying rare diseases, including ATTR amyloidosis, are expected to significantly increase the number of diagnosed patients, thereby driving market growth. The expansion of clinical research initiatives focused on developing novel pipeline treatments for transthyretin amyloidosis and related conditions further strengthens market potential.
List of Prominent Players in the Transthyretin Amyloidosis Treatment Market:
• Acrotech Biopharma, LLC
• Alnylam Pharmaceuticals, Inc.
• AstraZeneca PLC
• Astellas Pharma Inc.
• BridgeBio Pharma, Inc.
• Bristol-Myers Squibb Company
• Ionis Pharmaceuticals, Inc.
• Johnson & Johnson
• Prothena Biosciences Limited
• Pfizer Inc.
• SOM Innovation Biotech, S.L.
• Abbvie, Inc.
• Sanofi
• Eidos Therapeutics, Inc
• BELLUS Health Inc
Market Dynamics:
Drivers-
The rising prevalence of transthyretin amyloidosis, particularly among the aging population, is a significant factor driving market growth. With the global elderly population projected to reach 1.5 billion, the incidence of ATTR amyloidosis is expected to rise accordingly. According to a report by Prothena, over 400,000 individuals globally are affected by wild-type ATTR amyloidosis (ATTRwt), while approximately 50,000 individuals suffer from hereditary ATTR amyloidosis (hATTR). Research from NCBI highlights that aging is a major risk factor for ATTRwt, with the heart being the primary organ affected. To enhance awareness and early diagnosis, various organizations have launched initiatives aimed at educating healthcare professionals and patients.
Curious About This Latest Version Of The Report? Enquiry Before Buying:
https://www.insightaceanalytic.com/enquiry-before-buying/2890
Challenges:
A key challenge in the transthyretin amyloidosis treatment market is the limited awareness among healthcare professionals, leading to misdiagnosis and improper treatment. Additionally, the high cost of newly approved medications presents a financial barrier to patient accessibility. For example, a study by Alnylam Pharmaceuticals, Inc. indicates that the annual cost of Patisiran and Inotersen treatments is approximately $450,000 USD, posing affordability concerns for patients and healthcare systems.
Regional Trends:
The North American market is anticipated to hold a dominant share in revenue due to increased diagnosis rates, growing treatment adoption, and expanding prescription volumes. A significant milestone in the region was Health Canada's approval of ONPATTRO, a treatment for hATTR polyneuropathy, which has contributed to greater access to innovative therapies.
Additionally, the Middle East and Africa are witnessing substantial market growth, driven by high unmet medical needs, rising approval rates for novel therapies, and increasing disease prevalence.
Unlock Your GTM Strategy:
https://www.insightaceanalytic.com/customisation/2890
Segmentation of Transthyretin Amyloidosis Treatment Market-
By Type-
• ATTR-PN
• ATTR-CM
By Therapy-
• Targeted Therapy
o Onpattro
o Inotersen
o Vyndaqel/Vyndamax
• Supportive Therapy
• Pipeline Therapy
By Disease Type-
• Hereditary Transthyretin Amyloidosis
o Polyneuropathy
o Cardiomyopathy
o Mixed Type
• Wild Type Amyloidosis
By Distribution Channel-
• Hospital Pharmacies
• Specialty Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa
Get more information:
https://www.insightaceanalytic.com/report/transthyretin-amyloidosis-treatment-market/2890
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.JPG
Contact us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Transthyretin Amyloidosis Treatment Market Exclusive Report with Detailed Study Analysis here
News-ID: 3971095 • Views: …
More Releases from Insightace Analytic Pvt Ltd.

Prochlorperazine Maleate Market Size, Share and Trends Analysis Report 2025-2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Prochlorperazine Maleate Market- (By Indication (Nausea and Vomiting Management, Vertigo, Mental Health Disorders (e.g., Schizophrenia)), By Dosage Form (Oral Tablets, Rectal Suppositories, Injectable Formulations), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End-User (Hospitals, Clinics, Ambulatory Surgical Centers, Homecare Settings)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research…

Primary Cells Market Survey Detailed Analysis and Forecast 2025-2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Primary Cells Market- (By Type (Hematopoietic, Dermatocytes, Hepatocytes, Gastrointestinal, Lung, Renal, Heart, Musculoskeletal), Origin (Human Primary Cells, Animal Primary Cells), End User (Life Science Research Companies, Research Institutes, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic, the Global Primary Cells Market Size is valued at USD…

Predictive Disease Analytics Market expected to Witness Huge Revenue Growth to 2 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Predictive Disease Analytics Market Size, Share & Trends Analysis Report By Component (Hardware, Software & Services), By Deployment (On-premise and Cloud-based), By End-user (Healthcare Providers, Healthcare Payers)- Market Outlook And Industry Analysis 2034"
The Global Predictive Disease Analytics Market is estimated to reach over USD 22.6 Bn by 2034, exhibiting a CAGR of 21.2% during…

Predictive Biomarkers Market Current Scenario with Future Trends Analysis to 203 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Predictive Biomarkers Market- (By Indication (Cancer, Neurological Disorder, Cardiovascular Disorder, Immunological Disorder, Others), By End-Use (Diagnostic Centers, Contract Research Organizations (CROs), Academic Research Institutes, Pharma & Biotech Companies, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic, the Global Predictive Biomarkers Market is expected to grow with…
More Releases for ATTR
Hereditary ATTR (hATTR) Amyloidosis Pipeline Insights 2025: EMA, PDMA, FDA Appro …
DelveInsight's, "Hereditary Transthyretin Amyloidosis Pipeline Insight" report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Hereditary Transthyretin Amyloidosis (hATTR) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive…
ATTR Amyloidosis Pipeline: 10+ Leading Companies Shaping the Future of Groundbre …
The ATTR amyloidosis therapeutics market is witnessing a significant evolution, driven by trailblazing companies such as Novo Nordisk, Sirnaomics, and Arbor Bio. With the advent of RNA interference therapies, TTR stabilizers, gene-editing platforms, and next-generation silencers, these innovators are transforming the treatment landscape. The focus is sharply on halting disease progression, enhancing quality of life, and extending survival in both hereditary and wild-type ATTR amyloidosis. As targeted approaches gain momentum,…
US ATTR Market 2023 Share, Size, Key Players, Revenue Analysis | Prudent Markets
The US ATTR Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global US ATTR market. This report explores all the key factors affecting the growth of the global US ATTR market, including…
Transthyretin Amyloidosis (ATTR) Therapeutics Market Report, History and Forecas …
Transthyretin Amyloidosis (ATTR) Therapeutics Market 2021 by Technology, Manufacturers, Regions, Type, and Application, Forecast guide to light the excellent analysis on the market synopsis. The report offers a primary focus on important factors in the global Transthyretin Amyloidosis (ATTR) Therapeutics industry. The report includes perceptive information about gross revenue, cost, value, capacity, pricing, and profit margins concerning historical analysis and forecast estimation for the 2021 to 2031 time period. It…
Australian Transthyretin Amyloidosis (ATTR) Therapeutics Market 2023 Is Ready to …
Report Overview
The Australian Transthyretin Amyloidosis (ATTR) Therapeutics Market size stood at USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Transthyretin Amyloidosis (ATTR) is a progressive and severe orphan disease. ATTR amyloidosis is a medical disorder marked by the formation of abnormal deposits of a protein called amyloid (amyloidosis) in the organs and tissues of the…
Transthyretin Amyloidosis (ATTR) Market 2022 | Detailed Report
The top-notch information research report published by markets and markets is a vital asset that offers qualitative and quantitative factors of the Transthyretin Amyloidosis (ATTR) market. The research study and methodologies mentioned in the report examine the critical vendors by considering their contribution to the global market. Furthermore, the report offers an in-depth insight into leading players’ performance based on revenue generation and client requirements. Also, the research report reveals…